JAK Inhibitors Offer New Treatment Options for Atopic Dermatitis: Peer Exchange Panel Discusses Pharmacists' Role in Recommending Systemic and Topical Agents.

Peer Exchange provided an overview of atopic dermatitis, the unmet needs that remain regarding treatment, the potential use of Janus Kinase (JAK) inhibitors in managing the condition, and the critical role of pharmacists. Rotolo discussed dupilumab (Dupixent), the first systemic therapy for atopic dermatitis approved by the FDA, which may cause an injection site reaction. [Extracted from the article]